TAMs increase the secretion of chemokine CXCL5, which not only recruits monocytes but also activates the PI3K/AKT/mTOR pathway in tumor cells, mediating therapeutic resistance and tumor cell survival [92]. The gene discussed is CXCL5; the disease is neoplasm.